Inhibrx Announces Participation in Upcoming Scientific Conferences
Inhibrx Biosciences announced it will present clinical data at three upcoming scientific conferences: the 2026 ESMO Congress in Madrid, the MSTS Annual Meeting in Miami, and the CTOS Annual Meeting in Seoul. Data will cover ordastobart (INBRX-106) in head and neck cancer, including a phase 2 primary analysis of the HexAgon-HN phase 2/3 study, and ozekibart (INBRX-109) in chondrosarcoma and Ewing sarcoma from the registrational phase 2 ChonDRAgon study.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.